Dermatology

AbbVie submitted FDA and EMA applications for upadacitinib (RINVOQ) in adults and adolescents with non-segmental vitiligo, supported by phase 3 Viti-Up data.

Phase 2 INTEGUMENT-INFANT study results show roflumilast cream 0.05% was well tolerated and improved disease severity in infants with atopic dermatitis.

Findings from phase 3 SHORE and COAST 2 trials showed amlitelimab met key efficacy end points in moderate to severe atopic dermatitis, supporting planned regulatory submissions.

A national survey found most patients with chronic inflammatory skin disease rely on flare-based care and report concerns about long-term topical steroid use.

Vimal H. Prajapati, MD, discusses the latest roflumilast cream data from the INTEGUMENT-PED trial for pediatric atopic dermatitis.

Join us for a recap of some of our top dermatology Puzzler cases from 2025.

See the full case of our most recent Puzzler quiz and view the correct diagnosis of this 19-year-old woman with painful, purpuric nodules in the phalanges of her fingers.

Can you guess the diagnosis?

Druhan Howell highlighted that pediatric patients using tapinarof cream experienced rapid symptom relief and improved quality-of-life measures, with no new safety concerns.

The target action date for roflumilast cream 0.3% for plaque psoriasis in children 2 to 5 years is set for June 29, 2026.

Sub-analysis of ADORING trials shows VTAMA cream improved skin clearance, symptoms, and patient-reported outcomes in children aged 2-17.

Can you guess the diagnosis?

A pair of phase 3 trials showed that AbbVie's daily upadacitinib 15 mg led to a 50% reduction in T-VASI 50 and a 75% reduction in F-VASI 75 at 48 weeks among adolescents 12 years and older.

New one-year data showed that baricitinib continued scalp, eyebrow, and eyelash regrowth in adolescents with severe alopecia areata.

A single injection once per 8 weeks vs once per 4 weeks demonstrated similar levles of skin clearance, for AD patients 12 years and older, according to a Fall Clinical announcement.

New patient- and caregiver-reported outcomes across 3 phase 3 trials demonstrated improved itch and reduced impact of AD on sleep in patients 2 years and older.

Indication expansions include hidradenitis suppurativa for patients 12 years and up, as well as for patients with uveitis aged 2 years and older.

Can you guess the diagnosis?

A pair of roflumilast clinical trial investigators react to the FDA approval of the 0.05% formulation to treat atopic dermatitis in children aged 2 to 5 years.

The once-daily, steroid-free cream can be used anywhere on the body for treatment and for any duration, according to Arcutis.

Watch our FDA pipeline news recap for the month of September 2025 as well as a preview of a key PDUFA date in October.

Ingrid Polcari, MD, highlights concerns with teen skin care trends and emphasizes simple, age-appropriate routines tailored to patient needs.

Ingrid Polcari, MD, discusses acne severity, treatment options, and the importance of persistence and open discussion in pediatric care.

From another potential treatment for pediatric atopic dermatitis, to STI therapy for uncomplicated urogenital gonorrhea, take a look ahead at key PDUFA dates in Q4.

FDA approves guselkumab as the first IL-23 inhibitor for children 6 years or older with plaque psoriasis or psoriatic arthritis.